See more : Revenio Group Oyj (REG1V.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Poxel S.A. (POXEL.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poxel S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Canadian General Investments, Limited (CGI.L) Income Statement Analysis – Financial Results
- International Conglomerate of Distribution for Automobile Holdings Co., Ltd. (3184.T) Income Statement Analysis – Financial Results
- Optomed Oyj (OPTOMED.HE) Income Statement Analysis – Financial Results
- Aptitude Software Group plc (APTD.L) Income Statement Analysis – Financial Results
- Electrocomponents plc (ECM.L) Income Statement Analysis – Financial Results
Poxel S.A. (POXEL.PA)
About Poxel S.A.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.98M | 674.00K | 13.40M | 6.81M | 26.56M | 74.61M | 5.29M | 70.27K | 59.65K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.98M | 672.00K | 59.00K | 551.00K | 0.00 | 0.00 | 0.00 | 0.00 | 25.19K | 23.21K | 15.60K | 0.00 | 0.00 |
| Gross Profit | 1.00K | 2.00K | 13.34M | 6.26M | 26.56M | 74.61M | 5.29M | 70.27K | 34.46K | -23.21K | -15.60K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.05% | 0.30% | 99.56% | 91.90% | 100.00% | 100.00% | 100.00% | 100.00% | 57.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.95M | 13.94M | 27.48M | 29.24M | 44.55M | 58.09M | 24.10M | 20.92M | 9.24M | 7.00M | 9.08M | 8.70M | 10.37M |
| General & Administrative | 5.03M | 4.44M | 10.63M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | 941.58K | 616.97K | 555.83K | 788.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 519.85K | 20.67K | 15.67K | 0.00 | 0.00 |
| SG&A | 5.03M | 4.44M | 10.63M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | 941.58K | 616.97K | 555.83K | 788.00K |
| Other Expenses | 2.79M | 3.51M | -2.31M | -2.52M | -733.00K | -512.00K | -353.31K | -398.37K | -137.06K | -1.04M | -2.43M | -2.13M | -2.47M |
| Operating Expenses | 28.77M | 21.89M | 35.80M | 36.65M | 51.23M | 62.07M | 27.19M | 24.35M | 11.78M | 6.90M | 7.27M | 7.12M | 8.68M |
| Cost & Expenses | 30.75M | 22.56M | 35.86M | 36.65M | 51.23M | 62.07M | 27.19M | 24.35M | 11.78M | 6.90M | 7.27M | 7.12M | 8.68M |
| Interest Income | 0.00 | 17.00K | 48.00K | 382.00K | 222.00K | 368.00K | 63.50K | 287.12K | 293.94K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.15M | 3.81M | 2.95M | 1.67M | 185.00K | 28.00K | 46.51K | 479.57K | 856.56K | 371.38K | 13.18M | 18.71K | -57.60K |
| Depreciation & Amortization | 17.20M | 555.00K | 556.00K | 551.00K | 424.00K | 62.00K | 37.90K | 32.01K | 22.98K | 12.34K | 15.39K | 15.34K | 13.68K |
| EBITDA | -12.17M | -28.02M | -22.52M | -29.72M | -24.59M | -2.81M | -21.87M | -23.15M | -11.31M | -15.64M | -23.32M | -9.40M | -11.32M |
| EBITDA Ratio | -614.49% | -3,203.26% | -157.30% | -453.78% | -90.97% | 16.89% | -419.91% | -34,115.64% | -19,255.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.76M | -21.89M | -22.46M | -29.85M | -24.67M | 12.54M | -21.90M | -24.28M | -11.72M | -6.90M | -7.27M | -7.12M | -8.68M |
| Operating Income Ratio | -1,451.99% | -3,247.77% | -167.66% | -438.54% | -92.90% | 16.81% | -414.02% | -34,558.20% | -19,649.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.32M | -9.51M | -1.30M | -1.98M | -1.07M | 13.29M | -395.11K | -1.30M | -905.06K | -7.19M | -13.18M | -18.71K | 57.60K |
| Income Before Tax | -35.09M | -31.40M | -23.76M | -31.82M | -25.74M | 13.60M | -22.30M | -24.48M | -12.24M | -14.08M | -20.45M | -7.14M | -8.62M |
| Income Before Tax Ratio | -1,771.23% | -4,658.16% | -177.35% | -467.56% | -96.93% | 18.23% | -421.50% | -34,843.71% | -20,521.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 2.00K | 2.00K | 2.00K | 36.00K | 1.00K | 77.00K | 395.93K | 200.62K | -124.24K | 72.02K | 13.18M | 18.71K | -57.60K |
| Net Income | -35.09M | -31.40M | -23.76M | -31.86M | -25.74M | 13.53M | -22.69M | -24.48M | -12.24M | -14.08M | -20.45M | -7.14M | -8.62M |
| Net Income Ratio | -1,771.33% | -4,658.46% | -177.37% | -468.09% | -96.93% | 18.13% | -428.99% | -34,843.71% | -20,521.40% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.91 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.99 | -1.16 | -0.68 | -0.80 | -1.16 | -0.72 | -0.86 |
| EPS Diluted | -0.91 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.99 | -1.16 | -0.68 | -0.80 | -1.16 | -0.72 | -0.86 |
| Weighted Avg Shares Out | 38.60M | 29.08M | 28.64M | 27.53M | 25.94M | 24.83M | 23.03M | 21.07M | 17.92M | 17.63M | 17.63M | 9.98M | 9.98M |
| Weighted Avg Shares Out (Dil) | 38.60M | 29.08M | 28.64M | 27.53M | 25.94M | 24.83M | 23.03M | 21.07M | 17.92M | 17.63M | 17.63M | 9.98M | 9.98M |
Source: https://incomestatements.info
Category: Stock Reports